Skip to main content

Week In Review: Shanghai Regor To Discover Metabolic Therapies For Lilly In $1.55 Billion Deal

Regor Therapeutics entered a $1.55 billion research pact with Eli & Lilly to discover therapies for metabolic disorders. Meanwhile, Beijing Avistone Pharma received a $200 million investment led by Vivo Capital to combine with Pearl Biotech.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.